Neuroleptic malignant syndrome;Síndrome neuroléptica maligna

Arquivos de Neuro-Psiquiatria

Volumn 69, Issue 5, 2011, Pages 751-755

  Moscovich, Mariana ^a   Nóvak, Felipe T M ^c   Fernandes, Artur F ^b   Bruch, Tatiana ^a   Tomelin, Tabita ^a   Nóvak, Edison M ^c   Munhoz, Renato P ^a,b   Teive, Hélio A G ^b  

^a PONTIFICAL CATHOLIC UNIVERSITY OF PARANÁ   (Brazil)

^b Movement Disorders Unit   (Brazil)

^c FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

Atypical antipsychotics; Neuroleptic malignant syndrome; Typical antipsychotics

Indexed keywords

AMANTADINE; BIPERIDEN; BROMOCRIPTINE; CHLORPROMAZINE; CLONIDINE; CLOZAPINE; DIAZEPAM; HALOPERIDOL; LEVODOPA; LEVOMEPROMAZINE; LITHIUM CARBONATE; MIDAZOLAM; NEUROLEPTIC AGENT; OLANZAPINE; PRAMIPEXOLE; QUETIAPINE; RISPERIDONE; THIORIDAZINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BIPOLAR DISORDER; CLINICAL ARTICLE; CROSS-SECTIONAL STUDY; DELIRIUM; DEMENTIA; DEMOGRAPHY; DIAPHORESIS; DRUG MEGADOSE; DRUG WITHDRAWAL; ENCEPHALITIS; FATALITY; FEMALE; HUMAN; HYPERSALIVATION; INFORMATION PROCESSING; MALE; MEDICAL HISTORY; MULTIPLE SCLEROSIS; NEUROLEPTIC MALIGNANT SYNDROME; PALLOR; PARKINSON DISEASE; PSYCHOSIS; SCHIZOPHRENIA; SYMPTOM; SYSTEMIC LUPUS ERYTHEMATOSUS; TACHYCARDIA; TACHYPNEA; URINE INCONTINENCE;

EID: 80455129833     PISSN: 0004282X     EISSN: 16784227     Source Type: Journal    
DOI: 10.1590/S0004-282X2011000600005     Document Type: Article

References (34)

1. Delay J, Pichot P, Lemperiere T, Elissalde B, Peigne F. A nonphenothiazine and non-reserpine major neuroleptic, haloperidol, in the treatment of psychosis. Ann Med Psychol 1960;118:145-152.
2. Levenson JL. Neuroleptic malignant syndrome. Am J Psychiatry 1985;142: 1137-1145.
3. Pelonero A, Levenson J, Pandurangi A. Neuroleptic malignant syndrome: a review. Psychiatric Services 1998;49:1163-1172.
4. Gillman PK. Neuroleptic malignant syndrome: mechanisms, interactions, and causality. Mov Disord 2010;25:1780-1790.
5. Szabadi E. Neuroleptic malignant syndrome. Br Med J 1984;288:1399-1400.
6. Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clin North Am 1993;77:185-202.
7. Strawn JR, Keck PE, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry 2007;164:870-876.
8. Hanel RA, Sandmann MC, Kranich M, De Bittencourt PR.Neuroleptic malignant syndrome: case report with recurrence associated with the use of olanzapine. Arq Neuropsiquiatr 1998;56:833-837.
9. Friedman LS, Weinrauch LA, D'Elia JA. Metoclopramide-induced neuroleptic malignant syndrome. Arch Intern Med 1987;147:1495-1497.
10. Khaldi S, Kornreich C, Choubani Z, Gourevitch R. Neuroleptic malignant syndrome and atypical antipsychotics: a brief review. Encephale 2008;34: 618-624.
11. Ciranni MA, Kearney TE, Olson KR. Comparing acute toxicity of first-and second-generation antipsychotic drugs: a 10-year, retrospective cohort study. J Clin Psychiatry 2009;70:122-129.
12. Ananth J, Parameswaran S, Gunatilake S, et al. Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry 2004;65:464-470.
13. Filice GA, McDougall BC, Ercan-Fang N, Billington CJ. Neuroleptic malignant syndrome associated with olanzapine. Ann Pharmacother 1998;32: 1158-1159.
14. Hasan S, Buckley P. Novel antipsychotics and the neuroleptic malignant syndrome: a review and critique. Am J Psychiatry 1998;155:1113-1116.
15. Gortney JS, Fagan A, Kissack JC. Neuroleptic malignant syndrome secondary to quetiapine. Ann Pharmacother 2009;43:785-791.
16. El-Gaaly S, St John P, Dunsmore S, Bolton JM. Atypical neuroleptic malignant syndrome with quetiapine: a case report and review of the literature. J Clin Psychopharmacol 2009;29:497-499.
17. Trollor JN, Chen X, Sachdev PS. Neuroleptic malignant syndrome associated with atypical antipsychotic drugs. CNS Drugs 2009;23:477-492.
18. Patterson JF. Neuroleptic malignant syndrome associated with metoclopramide. Southern Med J 1988;81:674-675.
19. Taylor NE, Schwartz HI. Neuroleptic malignant syndrome following amoxapine overdose. J Nerv Mental Dis 1988;176:249-251.
20. Mann SC, Caroff SN. Pathogenesis of neuroleptic malignant syndrome. Psychiatric Annals 1991;21:175-180.
21. Gurrera R, Romero J. Enzyme elevations in the neuroleptic malignant syndrome. Biol Psychiatry 1993;34:634-640.
22. Spivak B, Maline DI, Kozyrev VN, et al. Frequency of neuroleptic malignant syndrome in a large psychiatric hospital in Moscow. Eur Psychiatry 2000;15:330-333.
23. Caroff SN. The neuroleptic malignant syndrome. J Clin Psychiatry 1980; 41:79-83.
24. Shalev A, Hermesh H, Munitz H. Mortality from neuroleptic malignant syndrome. J Clin Psychiatry 1989;50:18-25.
25. Lazarus A, Mann SC, Caroff SN. The Neuroleptic malignant syndrome and related conditions. Washington, DC: American Psychiatric Press, 1989.
26. Velamoor VR, Swamy VR, Parmar LR, et al. Management of suspected neuroleptic malignant syndrome. Can J Psychiatry 1995; 40:545-549.
27. Reulbach U, Dütsch C, Biermann T, et al. Managing an effective treatment for neuroleptic malignant syndrome. Crit Care 2007;11:R4.
28. Weller M, Kornhuber J. A rationale for NMDA receptor antagonist therapy of the neuroleptic malignant syndrome. Med Hypotheses 1992;38:329-333.
29. Gordon PH, Frucht SJ. Neuroleptic malignant syndrome in advanced Parkinson's disease. Mov Disord 2001;6:960.
30. Adnet F. Neuroleptic malignant syndrome. Br J Anaesth 2000;85:129-135.
31. Berardi D, Dell'Atti M, Amore M, De Ronchi D, Ferrari G. Clinical risk factors for neuroleptic malignant syndrome. Hum Psychopharmacol 2002;17:99-102.
32. Keck PE, Pope HG, Cohen BM, et al. Risk factors for neuroleptic malignant syndrome. Arch Gen Psychiatry 1989;46:914-918.
33. Chandran GJ, Mikler JR, Keegan DL. Neuroleptic malignant syndrome: case report and discussion. CMAJ 2003;169:439-442.
34. Fink M, Taylor MA. The many varieties of catatonia. Eur Arch Psychiatry Clin Neurosci 2001;251:(Suppl 1)S8-S13.